Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 2/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445023 | 1.00 | ACP1 (0.65) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL16445025 | 1.00 | ACP1 (0.65) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL18154122 | 0.99 | ACP1 (0.64) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL18154121 | 0.99 | ACP1 (0.64) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL31442239 | 0.99 | ACP1 (0.64) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL18154211 | 0.91 | CSNK1D (0.59) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL18154214 | 0.91 | CSNK1D (0.59) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL31442476 | 0.91 | CSNK1D (0.59) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL18154170 | 0.89 | DYRK1A (0.58) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B | |
| SCHEMBL30794512 | 0.89 | DYRK1A (0.58) | ACP1DYRK1ACSNK1DCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | claimed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | claimed |
| US-20150148329-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-05-28 | — | — | US | claimed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | claimed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12343347-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-01 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20150148329-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | ACP1 3901/4885DYRK1A 4244/4885CSNK1D 2698/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | ACP1 1494/4885DYRK1A 3529/4885CSNK1D 382/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | ACP1 1469/4885DYRK1A 3599/4885CSNK1D 404/4885 |
| US-12343347-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, CYP3A5 | ACP1 3995/4885DYRK1A 4241/4885CSNK1D 1819/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
| US-20150148329-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | ACP1 3901/4885DYRK1A 4244/4885CSNK1D 2698/4885 |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | ACP1 932/4885DYRK1A 3437/4885CSNK1D 1707/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | ACP1 1159/4885DYRK1A 3736/4885CSNK1D 1728/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ACP1 1068/4885DYRK1A 3818/4885CSNK1D 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.